Effectiveness, cost effectiveness, acceptability and implementation barriers/enablers of chronic kidney disease management programs for Indigenous people in Australia, New Zealand and Canada: a systematic review of mixed evidence by unknown
RESEARCH ARTICLE Open Access
Effectiveness, cost effectiveness,
acceptability and implementation barriers/
enablers of chronic kidney disease
management programs for Indigenous
people in Australia, New Zealand and
Canada: a systematic review of mixed
evidence
Rachel Reilly1,2,3*, Katharine Evans4, Judith Gomersall1,2,6, Gillian Gorham4, Micah D. J. Peters2, Steven Warren5,
Rebekah O’Shea1, Alan Cass4 and Alex Brown1
Abstract
Background: Indigenous peoples in Australia, New Zealand and Canada carry a greater burden of chronic kidney
disease (CKD) than the general populations in each country, and this burden is predicted to increase. Given the
human and economic cost of dialysis, understanding how to better manage CKD at earlier stages of disease
progression is an important priority for practitioners and policy-makers. A systematic review of mixed evidence was
undertaken to examine the evidence relating to the effectivness, cost-effectiveness and acceptability of chronic
kidney disease management programs designed for Indigenous people, as well as barriers and enablers of
implementation of such programs.
Methods: Published and unpublished studies reporting quantitative and qualitative data on health sector-led
management programs and models of care explicitly designed to manage, slow progression or otherwise improve the
lives of Indigenous people with CKD published between 2000 and 2014 were considered for inclusion. Data on
clinical effectiveness, ability to self-manage, quality of life, acceptability, cost and cost-benefit, barriers and
enablers of implementation were of interest. Quantitative data was summarized in narrative and tabular form
and qualitative data was synthesized using the Joanna Briggs Institute meta-aggregation approach.
(Continued on next page)
* Correspondence: rachel.reilly@sahmri.com
1Wardliparingga Aboriginal Research Unit, South Australian Health and
Medical Research Institute, Adelaide, Australia
2Johanna Briggs Institute, Faculty of Health Sciences, University of Adelaide,
Adelaide, Australia
Full list of author information is available at the end of the article
© 2016 Reilly et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Reilly et al. BMC Health Services Research  (2016) 16:119 
DOI 10.1186/s12913-016-1363-0
(Continued from previous page)
Results: Ten studies were included. Six studies provided evidence of clinical effectiveness of CKD programs
designed for Indigenous people, two provided evidence of cost and cost-effectiveness of a CKD program, and
two provided qualitative evidence of barriers and enablers of implementation of effective and/or acceptable
CKD management programs. Common features of effective and acceptable programs were integration within
existing services, nurse-led care, intensive follow-up, provision of culturally-appropriate education, governance
structures supporting community ownership, robust clinical systems supporting communication and a central
role for Indigenous Health Workers.
Conclusions: Given the human cost of dialysis and the growing population of people living with CKD, there is
an urgent need to draw lessons from the available evidence from this and other sources, including studies in
the broader population, to better serve this population with programs that address the barriers to receiving
high-quality care and improve quality of life.
Keywords: Chronic kidney disease, Indigenous health, systematic review, chronic disease management
Background
Chronic Kidney Disease (CKD) occurs more frequently
and in younger age groups amongst Aboriginal and
Torres Strait Islander Australians than non-Indigenous
Australians, with rates three to five times the national
average in urban areas and up to 30 times the national
average in remote areas [1]. Mortality is correspondingly
high, with national data indicating CKD is a primary or
associated cause of death in 16 % of Indigenous deaths
[2]. A disproportionately high burden of CKD has also
been found among First Nations people in Canada and
Maori people in New Zealand, where there are similar
persistent patterns of heath inequities between Indigenous
and non-Indigenous people [3–5]. The incidence end-stage
kidney disease (ESKD) has almost doubled between 1991
and 2008 and is projected to increase by 130 % from 2009
to 2020 [2, 6]. Dialysis is expensive, invasive, and leads to
decreased quality of life, particularly for people living in
rural and remote locations, who often have to leave their
homes for extended periods and/or travel long distances to
access treatment [7].
Reducing this burden will require cross-sector primary
prevention strategies addressing risk factors across the
life course, including increasing access to appropriate
health care and early screening, [1, 8] as well as improved
access to effective and acceptable treatment programs for
those with CKD. This review is concerned with programs
targeting Indigenous people with established CKD and as
such has a deliberate focus on a narrow part of the treat-
ment continuum [9] (Fig. 1). The review was initiated by
renal staff working on the ‘front line’ in primary care set-
tings in central Australia, who expressed an urgent need
to find ways of stopping the rapid increase in ESKD, and
in particular of understanding what may assist those with
early-stage CKD to delay, or prevent, the need for dialysis.
The goals of CKD management programs include redu-
cing cardiovascular risk, identifying and managing compli-
cations, providing appropriate and timely interdisciplinary
health-care, and supporting lifestyle modifications [9–12].
A recent systematic review of CKD programs in the
United Kingdom, United States and Canada, found that
care provided by a multidisciplinary team, compared to
standard medical care, delayed the progression of CKD
[13]. The four studies included in this review focused on
education as the primary preventative strategy. A compre-
hensive preliminary search of relevant databases revealed
that there is no existing systematic review examining evi-
dence on the effectiveness, cost effectiveness, acceptability
and/or implementation barriers/enablers of CKD manage-
ment programs designed for Indigenous people living in
Australia or elsewhere.
The present review sought to address the following
questions:
1. What is the effectiveness of CKD programs designed
for Indigenous people in relation to outcomes,
including, though not limited to: clinical indicators
of CKD management such as blood pressure
control; the delayed progression of kidney disease/
time to dialysis; and quality of life?
Fig. 1 Focus of this review in relation to the prevention and management pathway for CKD
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2. What are the costs and costs relative to benefits of
CKD programs designed for Indigenous people from
the perspectives of individual patients and their
families, the primary health services that deliver
them, tertiary health services and society as a whole?
3. What do patient and provider experiences of CKD
programs designed for Indigenous people reveal
about the acceptability of programs, as well as
barriers and enablers of implementation?
Methods
A protocol for the review was published in the Joanna
Briggs Institute (JBI) Database of Systematic Reviews
and Implementation Reports [14]. This project was de-
veloped in accordance with the National Health and
Medical Research Council’s Values and Ethics: Guide-
lines for ethical research in Aboriginal and Torres Strait
Islander Research [15], and with the South Australian
Aboriginal Health Research Accord [16].
Search and study selection
The search strategy sought published and unpublished
studies in English, published between 2000 and 2014.
Earlier studies were considered less relevant due to ad-
vances in technology and data collection. Following the
JBI and Cochrane guidelines [17, 18], a four-step search
strategy was designed with a view to accessing the most
relevant published literature, and also took into account
the large amount of Indigenous health research evidence
contained in grey literature [19] (Table 1).
The PubMed search strategy is shown in Table 2.
The search results were imported into the EndNote
(Thomson Reuters) citation manager and pooled into a
single library. After removing duplicates, titles and abstracts
were screened against the inclusion criteria by two re-
viewers (RR and KE) working independently. Those articles
clearly not meeting the inclusion criteria were excluded.
The full texts of the remaining articles were examined and
those meeting the inclusion criteria were assessed for meth-
odological quality.
Assessment of quality of included studies
Two reviewers (RR and KE) assessed methodological
quality using relevant Joanna Briggs Institute (JBI) stan-
dardized critical appraisal instruments [17]. Quantitative
papers examining CKD program effectiveness were
assessed using the tools contained in the ‘JBI Meta-Analysis
of Statistics Assessment and Review Instrument’ (JBI-
MAStARI). JBI-MAStARI has separate tools for appraising
different study designs. In the absence of a specific tool
tailored for appraisal of uncontrolled before and after
studies, these were appraised using the ‘descriptive/case
series’ appraisal tool. Studies of costs and cost effectiveness
were assessed using the tools contained in the ‘JBI Ana-
lysis of Cost, Technology and Utilization Assessment and
Review Instrument’ (JBI-ACTUARI). Qualitative papers
were assessed using the tool in the ‘JBI Qualitative Assess-
ment and Review Instrument’ (JBI-QARI).
Any disagreements that arose between the reviewers
were resolved through discussion or with a third reviewer
(JG). Studies were classified as good quality if more than
80 % of appraisal characteristics were endorsed, moderate
quality if 50–80 % of characteristics were endorsed and
poor quality if less than 50 % were endorsed. Those rated
as poor quality were excluded.
Data extraction
Quantitative, economic and qualitative data were extracted
from papers included in the review by three reviewers
(RR, KE and JG) who worked independently using the
standardized data extraction tools from JBI-MAStARI,
JBI-ACTUARI and JBI-QARI [17]. Details about study
characteristics (e.g., interventions, populations, settings
and study methods) were extracted, as well as findings
for the outcomes/phenomena of interest relevant to the
review. Authors were contacted where necessary to clarify
reported data or access information not reported.
Data synthesis
The findings from included quantitative studies were
synthesized using narrative and tables. The findings of
qualitative studies were synthesized using the JBI meta-
aggregation synthesis tool in JBI-QARI. This involved
Table 1 Four-step search strategy
Step Search strategy
1 Limited search of PubMed and CINAHL, analysis of text words in titles and abstracts and of index terms used to describe the articles
2 Search using all identified keywords and index terms across all included databases: PubMed, EBSCO CINAHL, Embase, ATSIHealth via Informit
online, Web of Science, Psychinfo, Social Science Citation Index, APAIS Health databases, Australian Indigenous Health InfoNet and Primary
Health Care Research and Information Service (PHCRIS), Mednar, Trove, Google Grey, OCLC WorldCat Dissertations and Theses, Canada Theses
Portal and other sources: websites of relevant organizations in each country including Kidney Health Australia, Kidney Health New Zealand and
The Kidney Foundation of Canada, Australian Institute of Torres Strait Islander Studies, NativeWeb and World Health Organizationa
3 Search of reference lists of all identified reports and articles for additional studies
4 Search of all relevant published systematic reviews and consultation with experts
aSearches for each database available from the authors
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the aggregation of findings to generate a set of representa-
tive statements and categorizing the findings on the basis of
similarity in meaning. These categories were then subjected
to a meta-synthesis to produce a single, comprehensive set
of synthesized findings [17, 20]. The heterogeneity of stud-
ies in terms of interventions, populations, reported data
and study designs precluded both meta-analysis and second
level aggregated synthesis. As such, the results for each
question are presented separately below.
Results
Search and study selection
As shown in Fig. 2, the search returned 2246 unique ci-
tations that were screened by title and abstract against
the review inclusion criteria. The full texts of 136 papers
were then reviewed independently by the primary and
secondary reviewer (RR and KE), and reference lists
checked for additional relevant articles. Checking the
reference lists yielded one additional article that was in-
cluded for full-text examination. Of these 137 articles,
85 were excluded on the basis of study design, 23 on the
basis of population of interest, 2 were conducted in in-
patient settings and 12 were duplicates (eg. where there
were multiple publications from the same study). Four
articles were not accessible after extensive efforts to access
electronically and contacting the authors. A list of the stud-
ies excluded at full text examination with reasons for exclu-
sion is provided as an additional file. Of the ten included
studies, six provided quantitative evidence addressing the
question of intervention effectiveness, two on costs (1) and
cost effectiveness (1), two provided qualitative evidence on
barriers/enablers on CKD program implementation and
one study provided quantitative evidence on CKD program
acceptability.
Methodological quality of included studies
The majority of articles were rated as moderate quality,
two were good quality and one study of poor quality was
excluded [21]. Common weaknesses included a lack of
randomisation and insufficient follow-up period for
quantitative studies, a lack of clarity around the credibility
of values assigned to costs and outcomes for economic
studies, and the absence of a statement about the cultural
or theoretical position of the researcher, or addressing
their influence on the research for qualitative studies. The
critical appraisal tools are published in full elsewhere [17]
(Table 3).
Findings on the effectiveness of CKD programs
Study characteristics
As outlined in Table 4, of the six studies providing quan-
titative evidence on program effectiveness, four were
conducted in New Zealand [22–25] and two in Australia
[26, 27]. Four of these were uncontrolled prospective
cohort designs carried out over one [24, 25] or 2 years
[23, 27]. Of a number of possible publications reporting
effectiveness of the Menzies Renal Treatment Program
(MRTP), the thesis by Kondalsamy-Chennakesavan [26]
was selected because it was the most relevant and com-
prehensive, including two comparisons: 1) before and
after the MRTP was handed over to the Tiwi Health
Board (THB); and 2) outcomes from the MRTP versus
the THB-run Continuing Care Trial (CCT). Australian
participants were younger, on average, than the New




(Australia[mh] OR Australia*[tw] OR.au[ad] OR Australia*[ad] OR Northern Territory[tw] OR Northern Territory[ad] OR Tasmania*[tw]
OR Tasmania*[ad] OR New South Wales[tw] OR New South Wales[ad] OR Victoria*[tw] OR Victoria*[ad] OR Queensland[tw] OR
Queensland[ad] OR Canada[mh] OR Canad*[tw] OR.ca[ad] OR Canad*[ad] OR Alberta[tw] OR Alberta[ad] OR British Columbia[tw]
OR British Columbia[ad] OR Manitoba[tw] OR Manitoba[ad] OR New Brunswick[tw] OR New Brunswick[ad] OR Newfoundland and
Labrador[tw] OR Newfoundland and Labrador[ad] OR Northwest Territories[tw] OR Northwest Territories[ad] OR Nova Scotia[tw]
OR Nova Scotia[ad] OR Nunavut[tw] OR Nunavut[ad] OR Ontario[tw] OR Ontario[ad] OR Prince Edward Island[tw] OR Prince
Edward Island[ad] OR Quebec[tw] OR Quebec[ad] OR Saskatchewan[tw] OR Saskatchewan[ad] OR Yukon Territory[tw] OR Yukon
Territory[ad] OR New Zealand[mh] OR New Zealand[tw] OR.nz[ad] OR New Zealand[ad] OR Aotearoa[tw]) AND (Oceanic ancestry
group[mh] OR American Native continental ancestry group[mh] OR Maori[tw] OR Aborig*[tw] OR indigenous[tw] OR (Torres
Strait[tw] AND Islander*[tw]) OR Inuit*[tw] OR eskimo*[tw] OR native[tw] OR First Nation*[tw])
#2 Disease kidney diseases[mh] OR chronic disease[mh] OR chronic kidney[tw] OR chronic renal[tw] OR predialysis[tw] OR pre dialysis[tw] OR
albumin creatinine ratio[tw] OR estimated glomerular filtration rate[tw] OR diabetic nephropath*[tw]
#3 Intervention or
Setting
disease management[mh] OR health services, indigenous[mh] OR rural health[mh] OR rural population[mh] OR rural health
services[mh] OR preventive health services[mh] OR community networks[mh] OR delivery of health care[mh] OR health
planning[mh] OR case management[tw] OR intervention[tw] OR management[tw] OR service*[tw] OR model*[tw] OR program*[tw]
OR multidisciplinary[tw] OR co ordination[tw] OR coordination[tw] OR integrated[tw] OR transdisciplinary[tw] OR participatory[tw]
OR community[tw] OR care[tw] OR prevent*[tw] OR health education[tw] OR health promotion[tw] OR exercise[tw] OR rural[tw] OR
outreach[tw] OR remote[tw] OR focus group*[tw] OR ambulatory[tw] OR general practice[tw] OR clinic[tw] OR primary[tw] OR
outpatient[tw] OR telemedicine[tw]
#4 #1 AND #2 AND #3
Limits: Publication date from 01/01/2000–2014; English language.
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Zealand participants (weighted averages 44.1 years and
57.8 years respectively). The 437 participants overall
were split evenly between men and women (49.9 %
men).
Findings
Studies reported clinical indicators of CKD management
including blood pressure control, the use of anti-
hypertensive medication, albumin-creatinine ratio (ACR),
Fig. 2 PRISMA Diagram: Search and Study Selection
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glycemic index (HbA1c) and glomerular filtration rate. No
studies reported data on hard end-points such as dialysis or
death. There were also no data reported on quality of life or
other psychosocial variables, such as depression or stress.
Relevant clinical outcomes from all studies are shown
in Table 5. All intervention groups showed significant
reductions in systolic blood pressure from baseline or in
relation to comparator groups. All groups who reported
on ACR reported reductions, although this was non-
significant in Shephard [27] This study was limited by
very small sample size. Where it was reported, glycated
hemoglobin was lower at follow-up for most programs,
except for Kondalsamy-Chennakesavan [26], where re-
sults were mixed following the handover of the program
to the Tiwi Health Board when it was incorporate into
routine primary health care. Findings relating to esti-
mated glomerular filtration rate (eGFR) are also mixed.
eGFR is an important indicator of CKD function but is
complicated as a measure of program effect because it
can decrease in the short term with use of antihyperten-
sive medications. For many people with CKD, GFR re-
duces steadily over time, while for others it may follow a
non-linear trajectory [28].
Indicators of health knowledge and behavior were not
widely measured. Hotu et al. [22] measured medication
adherence by self-report questionnaire, and found that
80 % took their medication ‘most of the time’ in the
intervention arm, compared to 71 % in usual care. In
Shephard et al. [27], tablet counts indicated that 72 % of
participants took their medication at least 80 % of the
time. Walker et al. [24, 25] measured ‘self-management’
from the perspectives of patients and clinicians using 13
questions of the Partners in Health instrument [29] and
reported improvements in 12 of 13 domains.
















Q1. Was the assignment to
treatment groups truly
random?
Y Is the sample representative
of patients in the population
as a whole?
Y Was the study based
on a random or pseudo-
random sample?
N N N
Q2. Were participants blinded
to treatment?
N Are the patients at a similar
point in the course of their
condition?
N Were the criteria for
inclusion in the sample
clearly defined?
Y Y Y
Q3. Was allocation to treatment
groups concealed from the
allocator?
Y Has bias been minimized in
relation to selection of cases
and controls?
U Were confounding factors
identified and strategies
to deal with them stated?
N Y Y




Y Are confounding factors
identified and strategies to
deal with them stated?
Y Were outcomes assessed
using objective criteria?
Y Y Y
Q5 Were those assessing
outcomes blind to the
treatment allocation?
N Are outcomes assessed using
objective criteria?
Y If comparisons are being
made, were there sufficient
descriptions of the groups?
NA NA NA
Q6. Were the control and
treatment groups
comparable at entry?
Y Was follow-up carried out
over a sufficient time period?
Y Was follow-up carried out
over a sufficient time
period?
N N N
Q7. Were groups treated
identically other than for
the named interventions?
Y Were the outcomes of
people who withdrew
described and included in
the analysis?
Y Were the outcomes of
people who withdrew
included in the analysis?
N Y Y
Q8. Were outcomes measured
in the same way for all
groups?
Y Were outcomes measured in
a reliable way?
U Were outcomes measured
in a reliable way?
Y Y Y
Q9. Were outcomes measured
in a reliable way?
Y Was appropriate statistical
analysis used?
Y Was appropriate statistical
analysis used?
Y Y Y












Y yes, N no, U unclear. aGood: at least 80 %; Moderate: 50–80 %; Poor: less than 50 %
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Findings on the cost and cost effectiveness of CKD
programs
Study characteristics
Two studies provided evidence relating to costs or cost-
effectiveness of CKD programs from the perspective of
service providers. Baker et al. [30] measured the cost-
effectiveness of the Menzies Renal Treatment Program
(MRTP), which was also included in the quantitative
review [26], and Gador-Whyte et al. [31] compared the
estimated the costs of delivering best-practice care, as
defined by Central Australian Rural Practitioners’ Asso-
ciation (CARPA) guidelines [32], with actual expend-
iture for patients with Type 2 diabetes and/or CKD in
an Aboriginal Community Controlled Health Service in
remote Central Australia.
Findings
When comparing the MRTP to usual care, Baker et al.
[30] found that the risk of starting dialysis in the treatment
group relative to historical controls over a 4.7 year period
was reduced by 57 % (p = 0.03), as shown in Table 6.
Moreover, that over the 4.7 years, 36.8 person years of
dialysis were avoided by implementing the MRTP. The
reduced number of dialysis starts generated net savings
of $4.2 million (in 1997–1998 AUD). Sensitivity analysis
indicated that these findings were robust to changes in
costing assumptions (Table 7).
Gador-Whyte et al. [31] reported a total funding gap
of $198,728 per annum or $1733 per patient between
the projected cost of best practice care and actual ex-
penditure in 2009–2010. No sensitivity analysis was con-
ducted, therefore it is unclear whether funding gaps of
similar magnitudes have applied, and continue to exist,
in other ACCHS and community settings with different
staffing and cost structures. The study also identified
workforce shortages, low health literacy and a high acute
care workload as factors that may prevent delivery of
best practice care (Table 8).




















Q1. N N There is congruity between the stated
philosophical perspective and the
research methodology?
Y U Is there a well-defined question? Y Y
Q2. Y Y There is congruity between the
research methodology and the
research question or objectives?
Y Y Is there a comprehensive
description of alternatives?
NA NA
Q3. N N There is congruity between the
research methodology and the
methods used to collect data?
Y Y Are all important and relevant
costs and outcomes for each
alternative identified?
Y U
Q4. Y Y There is congruity between the
research methodology and the
representation and analysis of data?
Y Y Has clinical effectiveness been
established?
NA Y
Q5 N NA There is congruence between the
research methodology and the
interpretation of results?
Y Y Are costs and outcomes
measured accurately?
Y Y
Q6. U N There is a statement locating the
researcher culturally or theoretically
N N Are costs and outcomes valued
credibly?
Y U
Q7. N Y The influence of the researcher on the
research, and vice-versa, is addressed
N N Are costs and outcomes adjusted
for differential timing?
U Y
Q8. U N Participants and their voices are
adequately represented
Y Y Is there an incremental analysis of
costs and consequences?
N Y
Q9. NA Y The research is ethical according to
current criteria or evidence of ethical
approval by an appropriate body
Y Y Are sensitivity analyses conducted
to investigate uncertainty in
estimates of cost or
consequences?
N Y
Q10. Conclusions drawn in the research
report appear to flow from the analysis
or interpretation of the data
Y Y Do study results include all issues
of concern to users?
Y U
Q11. Are the results generalizable to
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Table 4 Characteristics of studies addressing question 1





























and lifestyle, dietary and
self-care education.
No comparator. 43 Pasifika patients
with type 2 diabetes,
CKD (mostly stages
2 and 3) and
hypertension. Mean
age 53 years, 77 %
male. 39 available





Walker et al. (2013,
2014) [24, 25]


















and clinical care plans
developed followed by
12 weeks of fortnightly
self-management sessions,
with monitoring to 12
months. Some outreach
and free care, medications
and transport.
No comparator. 52 patients (37 NZ
Māori, 10 Cook Island
Māori/Samoan and 5
NZ European) with





Hotu et al. (2010) [22] To determine whether a
nurse-led community-
based CKD program
involving a Māori or
Pasifika health care
assistant (HCA) (‘community
care’; CC) is more clinically
effective than ‘usual care’
(UC).











HCA to monitor BP,
promote adherence and
provide free transport.






Usual care by GP and
renal clinic.
65 Māori and Pasifika




n = 33; UC: n = 32).
Mean age: CC: 63; UC:
60 years; % male: CC:
55 %; UC: 53 %. 58
available for follow-up
at 12 months (CC:







To determine the clinical
effectiveness (and
acceptability- see below)
of the Umoona Kidney















delivering ACR point of
care tests (POCT) and
ascertaining acceptability





No comparator. 35 Aboriginal patients
with hypertension
and with or at risk of
CKD (20 had
albuminuria). Mean
age 49 years, 54 %
male. Patients
followed for a mean
of 15 months with

























1) To determine whether
improvements in BP and
metabolic control were
sustained following the
handover of the visiting
specialist-run MRTP to the
local THB.2) To compare




2.5 and 5.5 year retrospective
uncontrolled cohort study,
comparing cohorts:1)
66 month MRTP cohort
(n= 101) comparing pre-
handover (1995–1999) and
post-handover (2000–2001).2)
30 month MRTP (n= 149)
and CCT (n= 89) cohorts
comparing pre-handover




80 km north of
Darwin.
The MRTP was a specialist-
run project that ran
alongside the local health










a chronic disease care
plan and were managed
in routine PHC setting.







CKD (mostly stages 1
and 2). Mean age:
MRTP: 44; CCT:
42 years; % male:
















Table 5 Findings relating to question 1





















MRTP (n = 149)




Pre-(n = 101) Post-(n = 101)
Systolic Blood Pressure
mmHg(SD)























5.7 (1.2–15.2) 4.3 (1.3–16.7) NA NA NA NA




110 118* NA NA NA NA




NA NA NA NA NA NA
*p < 0.05 from baseline to follow-up
**p < 0.05 program vs. comparator at follow-up in Hotu et al. (2010) [22]
#Hotu et al. (2013) measured 24h urinary protein
aSE converted to SD (SD = N√SE)
bMmol/mol converted to %














Findings on acceptability and barriers/enablers of
implementation
Study characteristics
The two qualitative studies included in the review, from
Australia and New Zealand, described experiences of
CKD programs/models of care to Indigenous people from
the perspective of providers. Characteristics of included
qualitative studies are shown in Table 9. Tchan et al. [33]
evaluated the Outback Vascular Health Service (OVHS),
described as a chronic disease outreach program. The
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To assess, from a
government health
service perspective,
if the MRTP reduced











































Measured at 3 and
4.7 years.
Table 7 Comparison of the effects and costs of the MRTP and control at 4.7 years (Baker et al.) [26]
MRTP Control Difference
Number of client years 897.8 897.8
Program delivery cost (incremental) $987,926 $0 $987,926
Endpoint: ESKD treatment
ESKD treatment years incurred 27.7 64.5 −36.8
ESKD treatment costs incurred $3,120,350 $7,265,796 –$4,145,446
Total cost (program and ESKD costs) $4,108,276 $7,265,796 –$3,157,521
Endpoint: dialysis start
Relative risk for treatment versus control 0.43 (0.19–0.96), p = 0.012
Reduction in risk of starting dialysis in the treatment versus control 57 %, p = 0.03
Number of dialysis starts 11 26 −15
Lifetime ESKF treatment costs incurred $3,853,332 $9,107,875 –$5,254,543
Total cost (program and lifetime ESKD costs) $4,841,258 $9,107,875 –$4,266,618
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study documents service provider experiences of provid-
ing care to Aboriginal people with CKD, which reveal bar-
riers and enablers of implementing acceptable and
effective CKD care to Aboriginal people. Walker et al. [34]
is a descriptive, exploratory study describing pre-dialysis
nurses’ experiences of delivering care to CKD patients on
outpatient clinics. It offers evidence relating to barriers
and enablers to providing effective CKD care to Maori
and Pasifika patients.
Shephard et al. [27] present the results of a brief sur-
vey of program acceptability developed for the Umoona
Kidney Program. This 7-item questionnaire was admin-
istered to 50 Aboriginal community members, including
the participants in the program. Items such as ‘Are you
happy with the way the kidney team treats you?’ were
measured on a 5-point scale from ‘very much yes’ to
‘very much no.’
Findings
Twenty-nine findings on barriers or enablers of CKD
program implementation were identified and extracted
from the two qualitative studies. Twelve unsupported
findings (those without supporting data) in Tchan et al.
[33] were excluded. The 17 remaining findings, summa-
rized in Fig. 3, were grouped into four categories. These
categories were synthesized into one overall finding.
There was no qualitative evidence from the perspectives
of patients.
The survey of acceptability reported by Shepard et al.
[27] found very positive attitudes amongst community
members towards the Umoona Kidney Project. However,
the small sample and bias inherent in the phrasing of
questions and mode of administration make this ques-
tionnaire difficult to interpret with confidence.
Discussion
The purpose of this review was to examine evidence on
the effectiveness, cost effectiveness and acceptability
CKD management programs for Indigenous people, as
well as barriers and enablers of implementation. Given
the broad scope of these questions, which were directed
at providing guidance for the design and implementation
of future CKD programs, the inclusion criteria were
broad and inclusive in regards to the types of programs
and outcomes considered. In light of this, the small
number of included studies, in particular addressing
questions 2 and 3, was surprising. An examination of the
studies excluded from this review indicates that there is
a lot written but not a lot of it is intervention research.
While the heterogeneity, small sample sizes and moder-
ate quality of the included studies limit generalizability,
the findings do indicate that targeted CKD programs are
effective in improving clinical outcomes for Indigenous
people with CKD, such as maintaining blood pressure
within target ranges and reducing HbA1c and albumin-
uria. Alongside data on the effectiveness of programs,
the inclusion of evidence on cost, cost-effectiveness, ac-
ceptability, and barriers and enablers of implementation
was considered important for informing the future pro-
gram development, given the unique economic, social
and cultural contexts in which CKD programs for Indi-
genous peoples are implemented. The small quantity of
Table 8 Costs of usual and best practice care for patients in an ACCHS setting (Gador-Whyte et al.) [27]
Estimated 2009–10 costs ($) Projected best practice costs ($) Difference ($)
Costs for diabetes and CKD care in a remote ACCHS Annual Per patient (mean) Annual Per patient (mean) Annual Per patient (mean)
446,585 6123 645,313 7856 −198,728 −1733
Table 9 Characteristics of studies addressing question 3
Study Study design Setting Participants Study objectives
Tchan et al.
(2012) [30]
Mixed methods study. Qualitative
component used a descriptive,
exploratory approach. Semi-







20 service providers comprising 4
medical specialists, 6 managers, 2
Aboriginal health workers (AHWs),
5 GPs, 3 local Aboriginal employees.
To understand provider views
on the implementation of the
Outback Vascular Health Service
(OVHS), a chronic disease
outreach program that operated






and thematic analysis guided by






11 pre-dialysis nurses working with
large case-loads of clients approaching
ESKD, including a significant proportion
of Māori and Pasifika patients.
To understand perceptions of
pre-dialysis specialist nurses
on factors influencing their





measured on a 5-point scale and
administered by either AHWs,
the nurse in charge, community




50 community members including 27
participants in the Umoona kidney
program
To determine the acceptability
of the Umoona Kidney Project
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research addressing these questions suggests that little
is currently known about the how CKD management
programs for Indigenous peoples are experienced, in
particular from the perspectives of clients, their families
or communities; and also indicates that economic
evaluation is not routinely included in CKD program
evaluation. Nonetheless the body of evidence included
in the review provides a useful indication of the par-
ticular features that should be considered in the design
of CKD management programs for Indigenous people.
All programs were multifaceted. While it is not possible
to draw conclusions about the particular components of
programs that may be causally related to improved out-
comes, we identified characteristics common to many of
the programs. Future qualitative and quantitative research
could explore these questions more fully. Common com-
ponents of effective programs were: the integration or co-
ordination with primary care; nurse-led or Indigenous
Health Worker-led care; intensive follow-up including
home-visits; the provision of anti-hypertensive medication
following a step-wise protocol; and addressing barriers to
adherence such as cost and lack of transport. Education
also emerged as a key component of effective programs,
but it had to be delivered in ways that accounted for liter-
acy and culture. These program features were consistent
with the findings addressing the question of acceptability,
and barriers and enablers of implementation. There is also
overlap between these findings and evidence in non-
Indigenous populations, which indicates that nurse-led
and/or multidisciplinary [13, 35], protocol-driven [36] care
embedded in primary health care and including patient
education tends to lead to better outcomes [13, 35, 36].
To address the question of cost and cost effectiveness
(Q2), we sought to identify studies of CKD management
programs that considered cost and cost-effectiveness in
their evaluations. Such studies involve weighing up factors
and conditions specific to a particular time and context.
As such, our ability to draw generalizable conclusions
from the two included studies is limited. For example, the
effectiveness data in Baker et al. [30] should be considered
in light of the medical advances that have occurred in rou-
tine practice since the data was collected between 1995
and 1998 (although the study was published in 2005).
Similarly, Gador-Whyte et al. [31] conducted their study
in 2010–2011, and since that time relevant changes to the
funding structures of Aboriginal Community Controlled
Health Organizations have occurred, such as the introduc-
tion of the Practice Incentive Program (PIP) Indigenous
Health Incentive, which provides eligible Indigenous health
services with a payment for each patient who is registered
Fig. 3 Synthesis of qualitative findings addressing question 3
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for chronic disease care, and an additional payment for
those who receive a target level of care in a calendar
year [37, 38].
Nonetheless, the studies provide some insights relating
to the resourcing of CKD programs. Gador-Whyte et al.
[31] provide a valuable outline of what constitutes best-
practice care in a remote Aboriginal Health Service. The
funding short-fall between projected (best-practice) and
actual expenditure appeared across clinical staff, admin-
istrative staff and other operating costs. It was noted that
an acute work-load, health literacy, under-staffing and
high staff turnover were barriers to the provision of
best-practice care, reflecting broader issues such as the
challenge of recruiting and retaining staff in remote
communities, rather than a funding shortfall per se.
Baker et al. [30] suggest that from a government per-
spective, the Menzies Renal Treatment Program was a
‘good buy’ for health, as it generated improvement in
health outcomes and reduced suffering for patients, as
well as monetary savings by reducing dialysis start num-
bers. The positive impact on quality of life is the stron-
ger and, arguably, sufficient argument for investing in
primary and secondary prevention programs. Further-
more, effective management of CKD is likely to have
additional benefits for the prevention of other acute and
chronic health problems (such as cardiovascular disease),
leading to other social and economic benefits that should
be taken into account.
Regarding the question of acceptability, and barriers
and enablers of implementation (Q3), the two studies in-
cluded in this review reveal important enablers to imple-
menting CKD management programs to Indigenous
people such as governance structures that support com-
munity ownership and culturally relevant care; flexible
care that can meet the needs of people in their particular
context; and robust clinical systems that support com-
munication, staff autonomy and capacity building. In
particular, the important role of nurses and Indigenous
Health Workers was again highlighted in both studies.
These program features are in line with Gibson et al.
[39] who found that community engagement, coordin-
ation of care, embedding culturally safe care, for example
by employing Indigenous people, and respecting patients’
perspectives enabled the implementation of chronic
disease care. Excluding IHWs from decision-making
and poorly performing electronic support systems were
barriers to implementation.
Conclusions
Overall, the findings of this review point to the benefit
of CKD care that caters to people in their social and cul-
tural environments. That is, care that is embedded
within existing healthcare services that people already
use. Health services utilising intensive outreach aim to
remove barriers to adhering to medical regimens and at-
tending appointments, as well as enabling education and
assisting with goal setting in an appropriate location for
individuals and families. The role of nurses and/or Indi-
genous health workers was emphasised in delivering ef-
fective outreach and education, and the role of primary
health care services was emphasised, in line with recent
policy recommendations [39–41].
There is no doubt that more rigorous evaluations of
programs over longer time-frames would assist a better
understanding the longer-term effectiveness and sustain-
ability of CKD programs, and to understand the mecha-
nisms by which programs lead to change. Researchers
should also be encouraged to adhere to best practice by
outlining program theories, to enable the assessment of
program fidelity, and a better understanding of why and
how a program effect occurs. However, given the human
cost of dialysis and the growing population of people liv-
ing with CKD, there is a critical need to draw lessons
from the available evidence, including this and other
sources in Australia and internationally, to better serve
Indigenous people with programs that address the barriers
to receiving high-quality care and improve quality of life.
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